Abstract
What is the precise nature of the relationship between a firm’s research and development alliance portfolio size and its innovation output? The existing literature is inconclusive between a positive linear relationship and a nonlinear variant. To address the issue, this study explores the relationship between alliance portfolio size and innovation output in the context of the pharmaceutical industry. Contrary to previous investigations, our results suggest increasing returns at a diminishing rate at a low to moderate alliance portfolio level while exhibiting increasingly higher returns at a moderate to high level of portfolio size. An advantage of the present investigation is that we draw from a larger data set of alliance agreements compared to earlier investigations. Additionally, the results provide improved reliability compared to previous studies where violations of some underlying assumptions have been overlooked. The paper concludes with a discussion of findings and suggestions for future research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
